George Han, MD
Dermatology · New York, NYNPI 1912296963
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,019,124 of the $1,568,202 with a category attached, or 65.0%. It is spread thinly across 33 manufacturers, the largest accounting for just 14.9%. Among dermatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,366 payments — averaging $1148.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$234K
- E.r. Squibb & Sons, L.L.C.$215K
- Regeneron Healthcare Solutions, Inc.$213K
- UCB, Inc.$198K
- Sanofi$159K
- Sun Pharmaceutical Industries Inc.$151K
- plus $399K from 27 others
Across 184 payments — averaging $10,097 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$912K
- Eli Lilly$272K
- Regeneron$165K
- Amgen$144K
- Bristol Myers Squibb$138K
- Novartis$121K
- plus $105K from 2 others
What the payments were for
- Consulting fees$465,93430%
- Speaking & faculty fees$1,019,12465%
- Travel & lodging$52,5543%
- Food & beverage$29,9482%
- Education$6410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 210 | $233,593 |
| E.r. Squibb & Sons, L.L.C. | 127 | $214,643 |
| Regeneron Healthcare Solutions, Inc. | 154 | $213,020 |
| UCB, Inc. | 160 | $197,754 |
| Sanofi | 74 | $159,316 |
| Sun Pharmaceutical Industries Inc. | 119 | $150,986 |
| AbbVie | 155 | $104,646 |
| Pfizer | 65 | $51,426 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 66 | $45,883 |
| Dermavant Sciences, Inc. | 21 | $45,705 |
| Incyte Corporation | 53 | $42,348 |
| Lilly USA, LLC | 54 | $31,444 |
| Novartis | 23 | $13,624 |
| Hikma Pharmaceuticals USA | 3 | $13,200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $10,675 |
| Boehringer Ingelheim | 5 | $7,884 |
| Janssen Global Services, LLC | 4 | $6,588 |
| Janssen Scientific Affairs, LLC | 4 | $5,125 |
| LEO Pharma Inc. | 15 | $3,763 |
| LEO Pharma AS | 1 | $3,620 |
| Galderma Laboratories, L.p. | 2 | $3,300 |
| UCB SA | 2 | $2,675 |
| Janssen Research & Development, LLC | 1 | $2,600 |
| Amgen | 4 | $2,306 |
| EPI Health, LLC | 1 | $1,500 |
| Arcutis Biotherapeutics, Inc. | 13 | $254 |
| VYNE Pharmaceuticals Inc. | 4 | $83 |
| Strata Skin Sciences, Inc. | 1 | $59 |
| Prugen, Inc. Pharmaceuticals | 8 | $44 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $44 |
| Bristol Myers Squibb | 3 | $42 |
| Regeneron | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,568,202 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 37 | $141,438 |
| OtezlaApremilast | 19 | $85,558 |
| Tacrolimus | 12 | $1,095 |
| Clobetasol Propionate | 14 | $1,026 |
| Ketoconazole | 19 | $454 |
| Triamcinolone Acetonide | 13 | $141 |
| Minoxidil | 13 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $2,306 | $85,55819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
- Mark LebwohlNew York$733K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.